Human Pathology
Volume 40, Issue 9 , Pages 1224-1233 , September 2009

Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma

  • Luis O. González, MD

      Affiliations

    • Unidad de Investigación, Hospital de Jove, 33290 Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
    • Servicio de Anatomía Patológica, Hospital de Jove, 33290 Gijón, Spain
    • ,
  • María D. Corte, PhD

      Affiliations

    • Unidad de Investigación, Hospital de Jove, 33290 Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
    • ,
  • Sara Junquera, MD

      Affiliations

    • Unidad de Investigación, Hospital de Jove, 33290 Gijón, Spain
    • ,
  • Raquel González-Fernández, PhD

      Affiliations

    • Departamento de Fisiología, Facultad de Medicina, 15782 Universidad de Santiago de Compostela, Spain
    • ,
  • José M. del Casar, PhD

      Affiliations

    • Unidad de Investigación, Hospital de Jove, 33290 Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
    • Servicio de Cirugía General, Hospital de Jove, 33290 Gijón, Spain
    • ,
  • Carmen García, MD

      Affiliations

    • Unidad de Investigación, Hospital de Jove, 33290 Gijón, Spain
    • ,
  • Alejandro Andicoechea, PhD

      Affiliations

    • Unidad de Investigación, Hospital de Jove, 33290 Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
    • Servicio de Cirugía General, Hospital de Jove, 33290 Gijón, Spain
    • ,
  • Julio Vázquez, PhD

      Affiliations

    • Unidad de Investigación, Hospital de Jove, 33290 Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
    • ,
  • Román Pérez-Fernández, PhD

      Affiliations

    • Departamento de Fisiología, Facultad de Medicina, 15782 Universidad de Santiago de Compostela, Spain
    • ,
  • Francisco J. Vizoso, PhD

      Affiliations

    • Unidad de Investigación, Hospital de Jove, 33290 Gijón, Spain
    • Instituto Universitario de Oncología del Principado de Asturias, 33006 Oviedo, Spain
    • Servicio de Cirugía General, Hospital de Jove, 33290 Gijón, Spain
    • Corresponding Author InformationCorresponding author. Hospital de Jove, Servicio de Cirugía General, 33290 Gijón, Spain.

Received 2 September 2008 ,Revised 1 December 2008 ,Accepted 3 December 2008.

References 

  1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–10874
  2. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–8423
  3. Bertucci F, Viens P, Hingamp P, Nasser V, Houlgatte R, Birnbaum D. Breast cancer revisited using DNA array-based gene expression profiling. Int J Cancer. 2003;103:565–571
  4. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005;65:9155–9158
  5. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  6. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100:10393–10398
  7. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991–1996
  8. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–5374
  9. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688–694
  10. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol. 2003;12:27–34
  11. Jacquemier J, Ginestier C, Rougemont J, et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res. 2005;65:767–779
  12. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002;2:657–672
  13. Demers M, Couillard J, Belanger S, St-Pierre Y. New roles for matrix metalloproteinases in metastasis. Crit Rev Immunol. 2005;25:493–523
  14. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–433
  15. Meller D, Li DQ, Tseng SC. Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha. Invest Ophthalmol Vis Sci. 2000;41:2922–2929
  16. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516
  17. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–174
  18. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. Apmis. 1999;107:80–85
  19. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia. 2001;3:459–468
  20. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest. 1999;103:1237–1241
  21. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 1998;161:6845–6852
  22. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000;486:247–251
  23. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999;189:161–168
  24. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252–257
  25. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89:1270–1275
  26. Vizoso FJ, Gonzalez LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer. 2007;96:903–911
  27. Nielsen BS, Rank F, Lopez JM, et al. Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. Cancer Res. 2001;61:7091–7100
  28. Chantrain CF, Shimada H, Jodele S, et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 2004;64:1675–1686
  29. Wurtz SO, Schrohl AS, Sorensen NM, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer. 2005;12:215–227
  30. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245–2252
  31. Baker AH, George SJ, Zaltsman AB, Murphy G, Newby AC. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999;79:1347–1355
  32. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997;3:1623–1628
  33. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol. 2002;117:723–728
  34. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–168
  35. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863–14868
  36. Gonzalez LO, Pidal I, Junquera S, et al. Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse. Br J Cancer. 2007;97:957–963
  37. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127
  38. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32
  39. Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol. 1997;183:377–379
  40. Li HC, Cao DC, Liu Y, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node–negative breast carcinoma. Breast Cancer Res Treat. 2004;88:75–85
  41. Chenard MP, O'Siorain L, Shering S, et al. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer. 1996;69:448–451
  42. Ahmad A, Hanby A, Dublin E, et al. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression. Am J Pathol. 1998;152:721–728
  43. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867
  44. Daniel D, Chiu C, Giraudo E, et al. CD4+ T cell–mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 2005;65:2018–2025
  45. Adams TE, Alpert S, Hanahan D. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature. 1987;325:223–228

☆ This work was supported by a grant from FIS-PI040137 Fondo de invesrsión Sanitaria del Instituto Carlos III (FIS-Spain) and Obra Social Cajastur.

PII: S0046-8177(09)00075-6

doi: 10.1016/j.humpath.2008.12.022

Human Pathology
Volume 40, Issue 9 , Pages 1224-1233 , September 2009

Article Tools

* Image Usage & Resolution